SLS (SELLAS Life Sciences Group) 3-1 Month Momentum %: 50.21% (As of Jul. 11, 2026)


SLS SELLAS Life Sciences Group Inc SLS
25 GF Score
Price $12.76
View Full Analysis

What is SELLAS Life Sciences Group 3-1 Month Momentum %?

SELLAS Life Sciences Group SLS -5.52% 25 3-1 Month Momentum % is 50.21% as of Jul. 11, 2026. GuruFocus rates SLS with a GF Score™ of 25/100. Among 1,385 Biotechnology companies, SELLAS Life Sciences Group ranks better than 94.51% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-11), SELLAS Life Sciences Group's 3-1 Month Momentum % is 50.21%.

The industry rank for SELLAS Life Sciences Group's 3-1 Month Momentum % or its related term are showing as below:

SLS's 3-1 Month Momentum % is ranked better than
94.51% of 1385 companies
in the Biotechnology industry
Industry Median: -10.98 vs SLS: 50.21

SELLAS Life Sciences Group  (NAS:SLS) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

SELLAS Life Sciences Group 3-1 Month Momentum % Related Terms

SLS vs MBX, BHVN, PHVS: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, SELLAS Life Sciences Group's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SELLAS Life Sciences Group 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's 3-1 Month Momentum % falls into.


SLS
25GF Score
SELLAS Life Sciences Group Inc SLS
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SELLAS Life Sciences Group  (NAS:SLS) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of 50.21% mean?
SELLAS Life Sciences Group (SLS) has a 3-1 Month Momentum % of 50.21% as of Jul. 11, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on SELLAS Life Sciences Group and its competitors. According to the industry distribution chart, SELLAS Life Sciences Group ranks #76 out of 1385 companies in the Biotechnology industry, placing it in the top 5.5%.
Is SELLAS Life Sciences Group's 3-1 Month Momentum % too high?
SELLAS Life Sciences Group's current 3-1 Month Momentum % is 50.21%. Based on the distribution chart, SELLAS Life Sciences Group ranks #76 out of 1385 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's 3-1 Month Momentum % compare to MBX and BHVN?
According to the Biotechnology industry distribution chart, SELLAS Life Sciences Group ranks #76 out of 1385 companies for 3-1 Month Momentum %. This places SELLAS Life Sciences Group in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on SELLAS Life Sciences Group and its competitors. SELLAS Life Sciences Group's current 3-1 Month Momentum % is 50.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current 3-1 Month Momentum % of 50.21%. The current 3-1 Month Momentum % is 50.21%. SELLAS Life Sciences Group's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current 3-1 Month Momentum % is 50.21% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SELLAS Life Sciences Group Business Description

Other Exchanges RXK3:Germany
Address 7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
25GF Score

Get the complete analysis for SLS

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.76
Price